Aktienanalyse zu Cytosorbents Corp (CTSO)CTSOCytosorbents Corp

CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Cytosorbents Corp is currently not a strong buy. The stock is trading at $4.81, significantly down 63.33% year-to-date and 66.67% over the past year. Although the RSI is at 55.67, indicating some momentum, the forward P/E ratio of 7.20 suggests potential undervaluation, but the recent reverse stock split raises concerns about future performance. The main risk is the company's high debt-to-equity ratio of 772.97%, which could impact financial stability.

4 analysts cover CTSO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 0.75.